Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) – Research analysts at Cantor Fitzgerald issued their FY2019 earnings per share (EPS) estimates for Aquinox Pharmaceuticals in a research report issued to clients and investors on Tuesday, March 13th, Zacks Investment Research reports. Cantor Fitzgerald analyst W. Tanner anticipates that the company will earn ($1.59) per share for the year. Cantor Fitzgerald currently has a “Buy” rating and a $28.00 price objective on the stock.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last posted its earnings results on Monday, March 12th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.10).
Several other research analysts also recently commented on the company. ValuEngine raised Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd. Zacks Investment Research downgraded Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, March 16th. BidaskClub raised Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, February 14th. Guggenheim assumed coverage on Aquinox Pharmaceuticals in a research note on Thursday, February 8th. They issued a “buy” rating and a $26.00 price objective on the stock. Finally, Canaccord Genuity set a $22.00 target price on Aquinox Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, December 19th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. Aquinox Pharmaceuticals has an average rating of “Hold” and an average price target of $22.80.
NASDAQ AQXP opened at $13.44 on Thursday. Aquinox Pharmaceuticals has a 52 week low of $10.02 and a 52 week high of $16.90. The stock has a market capitalization of $326.76, a PE ratio of -6.28 and a beta of -14.31.
A number of institutional investors and hedge funds have recently modified their holdings of AQXP. D.A. Davidson & CO. raised its stake in Aquinox Pharmaceuticals by 42.8% during the 4th quarter. D.A. Davidson & CO. now owns 14,350 shares of the company’s stock valued at $169,000 after purchasing an additional 4,300 shares during the period. Investment Centers of America Inc. bought a new stake in Aquinox Pharmaceuticals during the 3rd quarter valued at approximately $175,000. Citadel Advisors LLC bought a new stake in Aquinox Pharmaceuticals during the 3rd quarter valued at approximately $194,000. Eversept Partners LLC bought a new stake in Aquinox Pharmaceuticals during the 4th quarter valued at approximately $235,000. Finally, Deutsche Bank AG raised its stake in Aquinox Pharmaceuticals by 157.6% during the 4th quarter. Deutsche Bank AG now owns 21,878 shares of the company’s stock valued at $257,000 after purchasing an additional 13,385 shares during the period. 91.45% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This article was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2018/04/08/aquinox-pharmaceuticals-inc-aqxp-to-post-fy2019-earnings-of-1-59-per-share-cantor-fitzgerald-forecasts.html.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Get a free copy of the Zacks research report on Aquinox Pharmaceuticals (AQXP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.